Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27040925 | 1.00 | CYP11B1 (0.34) | CYP11B1CYP11B2RIPK1HDAC4KCNH2 | |
| SCHEMBL25816494 | 1.00 | CYP11B1 (0.34) | CYP11B1CYP11B2RIPK1HDAC4KCNH2 | |
| SCHEMBL30020800 | 1.00 | CYP11B1 (0.34) | CYP11B1CYP11B2RIPK1HDAC4KCNH2 | |
| SCHEMBL31200474 | 1.00 | CYP11B1 (0.34) | CYP11B1CYP11B2RIPK1HDAC4KCNH2 | |
| SCHEMBL30020269 | 1.00 | CYP11B1 (0.34) | CYP11B1CYP11B2RIPK1HDAC4KCNH2 | |
| Hydrochloric Acid SCHEMBL30338946 | 0.98 | CYP11B1 (0.33) | CYP11B1CYP11B2RIPK1HDAC4KCNH2 | |
| Hydrochloric Acid SCHEMBL22608955 | 0.98 | CYP11B1 (0.33) | CYP11B1CYP11B2RIPK1HDAC4KCNH2 | |
| Hydrochloric Acid SCHEMBL30338807 | 0.98 | CYP11B1 (0.33) | CYP11B1CYP11B2RIPK1HDAC4KCNH2 | |
| Trifluoroacetic Acid SCHEMBL31205907 | 0.88 | HDAC4 (0.37) | CYP11B1CYP11B2HDAC4HCAR2 | |
| Trifluoroacetic Acid SCHEMBL30339058 | 0.88 | HDAC4 (0.37) | CYP11B1CYP11B2HDAC4HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534457-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| US-12528799-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2026-01-20 | — | — | US | disclosed |
| US-20250019373-A1 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASES | VORONOI INC. (KR) | 2025-01-16 | — | — | US | disclosed |
| US-20240317730-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | VORONOI INC. (KR) | 2024-09-26 | — | — | US | disclosed |
| EP-4421077-A1 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASES | Voronoi Inc. (KR) | 2024-08-28 | — | — | EP | disclosed |
| US-12037330-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2024-07-16 | — | — | US | disclosed |
| US-20240166640-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | VORONOI INC. (KR) | 2024-05-23 | — | — | US | disclosed |
| EP-4342895-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2024-03-27 | — | — | EP | disclosed |
| US-20240025888-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | VORONOI INC. (KR) | 2024-01-25 | — | — | US | disclosed |
| CN-116547281-A | Isoxazolidines as RIPK1 inhibitors and uses thereof | 赛诺菲 | 2023-08-04 | — | — | CN | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
| CN-115667251-A | Heteroaryl derivative compound and use thereof | 株式会社沃若诺伊生物 | 2023-01-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037330-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | CYP11B1 2833/4885CYP11B2 2585/4885RIPK1 1316/4885 |
| US-20240317730-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | ERBB2, EGFR, ERBB3 | CYP11B1 2833/4885CYP11B2 2585/4885RIPK1 1316/4885 |
| US-12528799-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | CYP11B1 952/4885CYP11B2 1263/4885RIPK1 4331/4885 |
| US-12534457-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | CYP11B1 946/4885CYP11B2 1285/4885RIPK1 3805/4885 |
| US-20240166640-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | ERBB2, EGFR, ERBB3 | CYP11B1 2833/4885CYP11B2 2585/4885RIPK1 1316/4885 |
| US-20250019373-A1 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASES | RIPK1, RIPK2, RIPK3 | CYP11B1 1775/4885CYP11B2 2217/4885RIPK1 1/4885 |
| US-20240025888-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | ERBB2, EGFR, ERBB3 | CYP11B1 2833/4885CYP11B2 2585/4885RIPK1 1316/4885 |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | CYP11B1 2940/4885CYP11B2 3141/4885RIPK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.